About KAICO
KAICO is a Healthcare company based in Fukuoka (Japan) founded in 2018. Manufacturer of portfolio of proteins and other biological cytokines and enzymes. KAICO has raised $8.15 million across 5 funding rounds from investors including Sojitz, Tokyo Century and FFG Venture Business Partners. Its chief executive, as recorded, is Kenta Yamato. KAICO offers products and services including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is KAICO Ltd.
Company details
KAICO was founded in 2018 and is based in Fukuoka, Japan, within the biotechnology sector. A portfolio of proteins, cytokines, and enzymes is produced using a silkworm-baculovirus expression system as the primary technology. These products serve applications in medicine and diagnostic reagents. Contract research services for protein expression are also provided, alongside specific items such as PNGase-F, bFGF, and NucA.
- Headquarters Fukuoka, Japan
- SectorsHealthcare
- Phone•••• ••••
- Website kaicoltd.jp/en
- Legal Name Kaico Ltd.
- Total Equity Funding$8.15M (USD)
in 5 rounds
- Latest Funding Round$3.77M (USD), Series B
Apr 2025
- InvestorsSojitz
& 9 more
Products & Services of KAICO
KAICO offers a comprehensive portfolio of products and services, including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements.
Offers custom protein production using silkworm system for research.
Provides tailored protein expression services for client needs.
Delivers trial protein expression to test feasibility.
Supplies reagents derived from silkworm-expressed proteins.
Develops supplements using recombinant proteins for various uses.
Creates veterinary and human vaccines via protein expression.
Funding Insights of KAICO
KAICO has successfully raised a total of $8.15M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $3.77 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.15M
- Total Rounds 5
- Last Round Series B — $3.77M
- Investors Count 10
All 5 funding rounds of KAICO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $3.77M | Series B | – | – | |
| Jan 2024 | $1.96M | Series A | – | Tokyo Century, ITOCHU Technology Ventures | |
| Dec 2021 | Series A | – | – | ||
| May 2020 | $2.41M | Series A | – | FFG Venture Business Partners | – |
| Oct 2018 | Seed | – | – | – |
10 investors in total: 10 institutional.
Investors in KAICO
KAICO has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Sojitz, Tokyo Century and FFG Venture Business Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ffg-venture.co.jp | ||||
Venture capital firm investing in early-stage startups | techv.co.jp/en/ | Minato, Japan | ||
| mizuho-vc.co.jp | ||||
| dgincubation.com | ||||
| higincapital.co.jp | ||||
| jmtc.co.jp | ||||
Provider of aircraft finance & leasing services | 1969 | tokyocentury.co.jp | Chiyoda City, Japan | |
Services across automobiles, energy, and resource sectors are offered globally. | 2003 | sojitz.com | Tokyo, Japan | |
| agri-invest.co.jp | ||||
| sagin-capital.co.jp |
Investor details for KAICO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KAICO
1 people are tracked at KAICO (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kenta Yamato | CEO | Leadership |
Complete people profiles for KAICO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of KAICO
3 dated milestones of KAICO across 7 years, from founding to its latest funding, stage changes and deals.
- Founded KAICO is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $3.8M.
Web traffic of KAICO
The website of KAICO (kaicoltd.jp) receives about 4.1K visits a month.
- Monthly visits4.1K
▲ 19.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kaico
Complete news archive for KAICO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KAICO
KAICO was founded in 2018.
KAICO is headquartered in Fukuoka, Japan. It is registered at Fukuoka, Fukuoka, Japan.
Kenta Yamato is the CEO of KAICO, as recorded in our data.
KAICO is a funded company, having raised a total of $8.15M across 5 funding rounds to date.
KAICO was founded in 2018 and is based in Fukuoka, Japan, within the biotechnology sector. A portfolio of proteins, cytokines, and enzymes is produced using a silkworm-baculovirus expression system as the primary technology. These products serve applications in medicine and diagnostic reagents. Contract research services for protein expression are also provided, alongside specific items such as PNGase-F, bFGF, and NucA.
KAICO offers Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and 2 more products and services.
KAICO has 10 investors. Key investors include Sojitz, Tokyo Century, FFG Venture Business Partners, ITOCHU Technology Ventures, and Mizuho Capital.
KAICO operates through Kaico Ltd..